The BRAF Knockout A-549 Polyclonal Cells comprise a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human A-549 lung adenocarcinoma cell line, engineered to disrupt the BRAF proto-oncogene. This polyclonal population offers a heterogeneous loss-of-function model suitable for pooled functional studies, enabling researchers to interrogate BRAF-dependent signaling without the selective pressure of clonal isolation. The product is designed for applications requiring targeted gene disruption in a non-small cell lung cancer (NSCLC) background, providing a versatile tool for cancer biology and signal transduction research.
The host A-549 cell line was established from the lung carcinoma of a 58-year-old Caucasian male. These cells exhibit adherent epithelial morphology and a hypotriploid karyotype, and they are characterized as KRAS wild-type, EGFR wild-type, and p53 wild-type. As a widely used model for human lung adenocarcinoma, A-549 retains key features of alveolar basal epithelial cells, making it particularly relevant for studies of NSCLC biology. The wild-type status of major oncogenic drivers in this line allows for unambiguous interpretation of BRAF-specific phenotypes, avoiding confounding crosstalk from mutated KRAS or EGFR.
BRAF encodes a serine/threonine-protein kinase that functions as a central node in the RAS?CMAPK/ERK signaling cascade. Upon activation by upstream RAS GTPases and growth factor receptors such as EGFR or FGFR, BRAF phosphorylates and activates MEK1 and MEK2, which in turn phosphorylate ERK1/2. Active ERK translocates to the nucleus and regulates transcription factors including ELK1, c-Myc, and c-Fos, ultimately driving gene expression programs that control cell proliferation, differentiation, and survival. BRAF activity is modulated by interacting partners such as 14-3-3 proteins, KSR1, CRAF, and HSP90, and its signaling output is terminated by phosphatases like DUSP6. Disruption of BRAF in this polyclonal knockout population abolishes its kinase function, leading to loss of MEK and ERK phosphorylation and downstream transcriptional attenuation.
In the A-549 background, which lacks activating mutations in KRAS and EGFR, BRAF knockout provides a clean model to assess the dependency of NSCLC cells on wild-type BRAF-mediated MAPK signaling. This is particularly valuable for studying intrinsic and adaptive resistance mechanisms to BRAF inhibitors such as vemurafenib and dabrafenib, as well as for identifying compensatory pathways such as PI3K-AKT, Hippo, or TGF-beta signaling. Because the cells retain functional p53 and wild-type EGFR, the model downstream targets of BRAF loss can be attributed directly to MAPK pathway disruption without interference from these common oncogenic drivers.
Research applications for the BRAF Knockout A-549 Polyclonal Cells are extensive. They are suitable for functional genomics screens aimed at identifying synthetic lethal interactions with BRAF deficiency, drug sensitivity profiling against targeted therapies, and mechanistic studies of MAPK pathway dynamics. Representative assays include Western blotting for phospho-ERK to confirm pathway inactivation, RT-qPCR for ERK target genes such as CCND1 and DUSP6, proliferation and apoptosis assays, migration and invasion assays, colony formation, and in vivo xenograft tumor growth models. For further details or custom inquiries, please contact Ascent Research.
